60 Quick summary: Medical researchers have discovered that blocking the inflammatory receptor IL1RAP can successfully disrupt the protective cellular network that allows pancreatic cancer to resist conventional treatments. Preclinical models demonstrate that inhibiting this specific receptor dramatically reduces tumour fibrosis and reactivates protective immune responses, paving the way for a pioneering clinical trial combining targeted therapy with chemoimmunotherapy. For healthcare practice and public policy, translating this bench to bedside research into active clinical regimens offers a vital breakthrough towards overcoming treatment resistance, improving survival rates for exceptionally lethal malignancies, and protecting long-term patient well-being. Blocking a key inflammatory receptor can disrupt the tumour-driven network that helps pancreatic cancer resist treatment, according to new research from Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine. The findings, published in JCI Insight, are now advancing towards a first-of-its-kind neoadjuvant clinical trial combining the experimental therapy with chemoimmunotherapy in patients with operable pancreatic cancer before surgery. Pancreatic cancer remains one of the most difficult cancers to treat, largely because of its tumour microenvironment, a complex network of cells that helps tumours resist chemotherapy and immunotherapy. Led by surgical oncologist Jashodeep Datta, MD, the study shows how IL1RAP, a receptor at a key control point in inflammatory signalling, connects tumour cells, immune cells, and fibroblasts into a coordinated network that sustains cancer’s resistance to treatment. “When we target IL1RAP, we are blocking a shared ‘helper’ receptor that many inflammatory signals rely on to transmit their message,” said Datta, co-leader of the Gastrointestinal Site Disease Group at Sylvester and senior author of the study. This “inflamed but immune-suppressed” environment is a major reason chemotherapy and immunotherapy often fall short in pancreatic cancer, and elevated IL1RAP helps tumours sustain their growth and treatment resistance. In preclinical models, inhibiting IL1RAP reshaped the tumour microenvironment. Immune-suppressive cells decreased, T cells became more active and effective, and tumours showed less fibrosis and improved response to combination therapy. Blocking IL1RAP also reduced overall tumour growth. “The goal is not just to attack cancer cells, but to reprogramme the environment that protects them, making existing treatments work better,” Datta explained. Based on these findings, a neoadjuvant clinical trial is now advancing at Sylvester, combining IL1RAP-targeted therapy with chemoimmunotherapy in patients with operable pancreatic cancer prior to surgery. The trial will allow researchers to evaluate tumours before and after treatment, offering a direct window into how a patient’s biology changes in response. “Moving this work into a clinical trial is a landmark development for our GI cancer programme at Sylvester,” Datta said. “We’re testing a clear, patient-centred strategy to disrupt IL1RAP using a treatment plan that can be delivered in the clinic.” Co-author Peter Hosein, MD, of Sylvester, said the trial creates an important feedback loop between laboratory science and patient outcomes. “Every new approach helps us learn more,” said Hosein. “This trial gives us a unique window to connect the science directly to patient outcomes, which is essential for moving the field forward.” The research is supported by a Translational Research Grant from the V Foundation, awarded to Datta and his team following national peer review. The grant provides $800,000 over four years to support bench-to-bedside research, advance novel strategies into early-phase clinical trials, and place the Sylvester team among a small cohort of funded translational teams selected each year. As the trial progresses, results could inform future strategies for broader pancreatic cancer populations, where persistently low survival rates continue to drive the search for new approaches.